EPISODE · Sep 10, 2026 · 10 MIN
今天3分钟我们来聊聊百万抗癌CAR-T药冲击医保谈判
from 源于细胞BioInsid的个人播客
2026年医保谈判中，百万级CAR-T产品纳基奥仑赛首次入围谈判，节目详解这款定制抗癌药的作用、高定价原因，以及高价细胞疗法尝试进入医保背后的多层次医疗支付体系变革意义。参考文献：合源生物美通社（2026-08-28）源瑞达®产品介绍 链接Blood Advances（2024-12-07）王建祥教授团队纳基奥仑赛治疗成人r/r B-ALL长期随访数据ASCO 2025 / EHA 2025 纳基奥仑赛真实世界97例数据（3月ORR 92.8%，MRD阴性率100%）国家医保局2026年国谈现场报道（9月5-9日，全国人大会议中心）国务院2025年商保创新药目录政策文件（双目录制度）前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊百万抗癌CAR-T药冲击医保谈判
0:00
10:50
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 10 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on September 10, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!